ArticleScientific reports2025

Post marketing safety surveillance of atezolizumab based on a retrospective analysis of the FDA adverse events reporting system (FAERS).

Gan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.